InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
前收盤價
US$14.21
+US$0.13 · +0.92%
盤中時間採用ET。市場資料可能有所延遲。
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
日內區間
目前US$14.21
52週區間
目前US$14.21
盤中時間採用ET。市場資料可能有所延遲。
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
日內區間
目前US$14.21
52週區間
目前US$14.21
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.7億 USD | 3.95億 USD | 4.92億 USD | 4.54億 USD | 3.58億 USD |
| 銷貨成本 | 7952.5萬 USD | 7775.2萬 USD | 8070.8萬 USD | 7348.5萬 USD | 5359.2萬 USD |
| 毛利 | 2.91億 USD | 3.17億 USD | 4.11億 USD | 3.81億 USD | 3.04億 USD |
| 研究與開發 | 1331.9萬 USD | 1313.7萬 USD | 1341萬 USD | 1242.5萬 USD | 953.2萬 USD |
| 銷售、一般及管理費用 | 1.92億 USD | 1.91億 USD | 2.02億 USD | 1.71億 USD | 1.28億 USD |
| 營業費用 | 2.06億 USD | 2.05億 USD | 2.16億 USD | 1.83億 USD | 1.36億 USD |
| 利息收入 | 2494.3萬 USD | 3093.8萬 USD | 2160.7萬 USD | 361.2萬 USD | 52.5萬 USD |
| 折舊和攤銷 | 69.5萬 USD | 72.8萬 USD | 62.3萬 USD | 68萬 USD | 51.7萬 USD |
| 營業利益 | 8538.7萬 USD | 1.13億 USD | 1.96億 USD | 1.98億 USD | 1.67億 USD |
| 淨利 | 9383.1萬 USD | 1.81億 USD | 1.98億 USD | 1.62億 USD | 1.65億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
iShares Core MSCI EAFE ETFIEFA784.23萬0.00%1894.71億 USD0.07%US$96.52+0.68%
iShares MSCI EAFE Small-Cap ETFSCZ242.02萬0.02%128.85億 USD0.40%US$83.93+0.82%
iShares Core MSCI Total International Stock ETFIXUS217.56萬0.00%586.25億 USD0.07%US$94.99+0.90%
ARK Israel Innovative Technology ETFIZRL195.92萬1.50%1.37億 USD0.49%US$28.36+1.61%
Avantis International Small Cap Value ETFAVDV147.71萬0.01%200.38億 USD0.36%US$108.52+0.74%
iShares MSCI Israel ETFEIS143.33萬0.17%8.6億 USD0.59%US$118.28+0.54%
Schwab Fundamental International Small Company Index ETFFNDC141.25萬0.05%30.73億 USD0.39%US$49.73+0.73%
iShares Core MSCI International Developed Markets ETFIDEV140.38萬0.00%331.28億 USD0.04%US$89.21+0.73%
iShares Core MSCI EAFE ETFIEFA
iShares MSCI EAFE Small-Cap ETFSCZ
iShares Core MSCI Total International Stock ETFIXUS
ARK Israel Innovative Technology ETFIZRL
Avantis International Small Cap Value ETFAVDV
iShares MSCI Israel ETFEIS
Schwab Fundamental International Small Company Index ETFFNDC
iShares Core MSCI International Developed Markets ETFIDEVAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。